Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03878342
Other study ID # UC-0107/1803
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 10, 2019
Est. completion date November 10, 2034

Study information

Verified date December 2023
Source UNICANCER
Contact Saliha GHANEM, PhD
Phone +33 1 80 50 12 98
Email s-ghanem@unicancer.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Following breast-conserving surgery (BCS) for localized ductal carcinoma in situ (DCIS) of the breast, whole-breast irradiation (WBRT) is a standard of care, reducing the absolute rate of in-breast recurrences (IBR) by more than 15% at 10 years, from 28% without radiotherapy to 13 % with radiotherapy. Half of the recurrences occurred as invasive disease. Whereas in the comparative trials, WBRT did not impact on overall survival, survival of patients who recurred with invasive cancers was impaired in comparison to patients who did not recur, or to patients with DCIS-only recurrences. Using criteria based on age, tumor size, nuclear grade, and margins status, several trials and cohort studies failed to identify subgroups of patients at low risk, who could be safely spared the need for WBRT. The Radiation Therapy Oncology Group (RTOG) DCIS trial included patients treated with BCS for low- or intermediate grade DCIS revealed by unifocal microcalcifications, size ≤25 mm, margins ≥3 mm, and no residual microcalcifications after surgery. The 5-year rates of IBR were 3.5 % without radiotherapy, versus 0.4 % with radiotherapy, and 6.7 % and 0.9 % at 7 years, respectively (p <0.001). Sixty percent of the patients received tamoxifen in both groups. Several studies showed that the same molecular classes were identified in DCIS as in invasive cancers. Studies suggested that low proliferation, hormone receptors expression, and lack of ERBB2 amplification were associated with a low risk of IBR in patients not receiving radiotherapy. A combined signature was tested in the Eastern Cooperative Oncology Group (ECOG) trial, showing a 10% IBR rate at ten years in patients with a low-risk. Identifying very low-risk DCIS, using biological markers in addition to the clinical and histological markers of low-risk DCIS, could help to select patients who could be safely avoided WBRT following BCS. It would avoid over-treatment in these women and could decrease the cost of management.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date November 10, 2034
Est. primary completion date November 10, 2029
Accepts healthy volunteers No
Gender Female
Age group 50 Years and older
Eligibility Inclusion Criteria: 1. Woman aged =50 years, 2. ECOG performance status =2 3. Microcalcifications on pre-biopsy mammography, unifocal, =25 mm or opacity without microcalcifications and no clinical palpable tumour 4. Absence of suspicious residual microcalcifications either on post-biopsy/ preoperative localization mammography, or on post-operative mammography Note: if absence of residual microcalcifications on post-biopsy/pre-operative mammography, post-operative mammography is not mandatory; 5. Breast-conserving surgical excision; 6. Histologically proven DCIS of the breast without an invasive component; Note Incidental histological finding of DCIS lesions developed within a benign breast lesion as well as an association with classical lobular carcinoma in situ (LCIS) associated with the DCIS are accepted. 7. Free margins (=2 mm), or free margins following re-excision; 8. Low or Intermediate nuclear grade; Note: In case of nuclear grade heterogeneity within the same sample or between the biopsy or the surgical specimen, the highest nuclear grade score will prevail. 9. Tumour tissue sample availability; Note: Surgical specimen is mandatory unless no residual disease on the surgical specimen. In this instance, the initial diagnosis biopsy is required. 10. Absence of extensive necrosis (=30% of the lumen diameter); 11. Immunohistochemical characteristics of luminal A subtype: ER=10 %, PR =20 %, HER2 negative (0/1+) or 2+ not amplified (confirmed by fluorescent in situ hybridization (FISH) or chromogenic in situ hybridization (CISH)), Ki67 <15%. 12. Patient willing and able to comply with the protocol for the duration of the study including undergoing treatment, scheduled visits and examinations and including follow-up; 13. Written informed consent. 14. Affiliation to the French social security. Exclusion Criteria: 1. Endocrine treatment for breast cancer. 2. Previous invasive breast cancer including contralateral breast cancer, either metachronous or synchronous 3. Previous DCIS except contralateral DCIS in complete and continuous remission for more than 5 years 4. Previous other cancers (except basal-cell, carcinoma in situ of the cervix or endometrium), not in complete and continuous remission for more than 10 years 5. Known breast-cancer predisposing germ-cell mutation; 6. Palpable tumour with a diagnosis of DCIS on biopsy 7. Bloody nipple discharge; 8. Histological size >25 mm in one or multiple foci 9. High nuclear grade, including high nuclear grade in heterogeneous tumours;either on biopsy or on surgical specimen 10. Associated microinvasive or invasive component; 11. Presence of tumour cells in lymph nodes detected using H&E or immunohistochemical examination (if lymph node sentinel biopsy or dissection has been performed); 12. Absolute contra-indication to whole-breast irradiation as determined by the referring physician; 13. Patient unable to comply with study obligations for geographic, social, or physical reasons, or who is unable to understand the purpose and procedures of the study. 14. Pregnant women or breast feeding mothers,

Study Design


Intervention

Radiation:
Radiotherapy
two fractionation regimens will be allowed for whole-breast irradiation: 50 Gy in 25 fractions over 5 weeks or 40 Gy in 15 fractions over 3 weeks. The delivery of an additional dose to the tumour bed (boost) will be at the referring physician discretion, according to the guidelines
Other:
No Radiotherapy
No Irradiation- Active surveillance

Locations

Country Name City State
France Institut de Cancérologie de l'Ouest -Site Paul Papin Angers
France Institut Sainte Catherine Avignon
France Centre d'Oncologie et de Radiothérapie du Pays Basque Bayonne
France Clinique Belharra Bayonne
France Institut Bergonie Bordeaux
France Centre Francois Baclesse Caen
France Centre Hospitalier du Cotentin Cherbourg
France Centre Jean Perrin Clermont-Ferrand
France CHIC Créteil Créteil
France Hôpital Henri Mondor Créteil
France Centre Georges Francois Leclerc Dijon
France Centre Hospitalier De Lagny Sur Marne Jossigny
France CHU Saint-Pierre La Réunion La Réunion
France Centre Guillaume le Conquérant Le Havre
France Centre Oscar Lambret Lille
France Chu De Limoges - Hopital Dupuytren Limoges
France Centre Hospitalier Bretagne Sud Lorient
France Centre de Radiothérapie Mermoz Lyon
France Centre Léon Berard Lyon
France Hôpital La Croix Rousse Lyon
France Institut Regional Du Cancer Montpellier Val D Aurelle Montpellier
France Centre Azuréen De Cancérologie Mougins
France Centre Antoine Lacassagne Nice
France Centre de Haute Energie Nice
France Hopital Pitie Salpetriere Paris
France Institut CURIE Paris
France Centre Hospitalier Lyon Sud Pierre-Bénite
France Institut Jean Godinot Reims
France Centre Eugène Marquis Rennes
France Centre Frédéric Joliot Rouen
France Centre Henri Becquerel Rouen
France Hôpital René Huguenin - Institut Curie Saint-Cloud
France CHU Saint-Etienne Saint-Étienne
France Centre De Radiothérapie De La Robertsau Strasbourg
France Centre Paul Strauss Strasbourg
France Institut Claudius Regaud Toulouse
France Institut De Cancerologie De Lorraine Alexis Vautrin Vandœuvre-lès-Nancy
France Gustave Roussy Villejuif

Sponsors (2)

Lead Sponsor Collaborator
UNICANCER National Cancer Institute, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary 5-year cumulative incidence of in-breast cancer recurrences Incidence of breast recurrence is determined from the date of last surgery to the date of breast recurrence. 5 years
Secondary Overall survival (OS) OS is defined as the interval between the date of last surgery and the date of death from any cause; 10 years
Secondary Breast cancer-specific survival (BCSS) BCSS is defined as the interval between the date of last surgery and the date of death from breast cancer 10 years
Secondary Relapse-free survival (RFS) RFS is defined as the interval between the date of last surgery and the date of ipsilateral breast recurrence, regional nodes recurrence, distant metastases, of death from breast cancer, whichever occurs first 10 years
Secondary Rate of in-breast recurrences (IBR). In-breast recurrence defined as any carcinoma (invasive or in situ) occurring in the treated breast 10 years
Secondary Rate of Contralateral breast Contralateral breast cancer defined as any carcinoma (invasive or in situ) occurring in the contralateral breast. 10 years
Secondary Quality of life of the patients using EORTC-QLQ-C 30 Quality of life will be assessed using QLQ-C 30 questionnaire from the European Organization for Research and Treatment of Cancer (EORTC). It is a 30-item self-reporting questionnaire developed to assess the quality of life of cancer patients. It is grouped into five functional subscales (role, physical, cognitive, emotional and social functioning). In addition, there are three multi-item symptom scales (fatigue, pain, and nausea and vomiting), individual questions concerning common symptoms in cancer patients,and two questions assessing overall Quality of Life 3 years
Secondary Quality of life of the patients using EORTC-QLQ-BR23 Quality of Life of Patients will be assessed using a EORTC-QLQ BR23.It is a 23-item self-reporting specific questionnaire developed to assess the quality of life of breast cancer patients. It permits to evaluate the symptoms of breast cancer and the side effects of treatment. 3 years
Secondary Cosmetics Evaluation cosmetic results will be evaluated by centralized photographic analysis. 3 years
Secondary Long term toxicities The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders and so the late effects and sequelea regarding the whole-breast radiotherapy. Throughout study completion, up to 10 years.
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2